that's correct but also just look above at the 3rd link down:
"Site has applied for Licensed Producer Status under the Marihuana for Medical Purposes Regulations as defined by Health Canada."
and Nizz my $15 estimate is based off the worst case scenario, very high dilution, about 35m shares more than are currently outstanding and low retained earnings. Of course I think the stock could be in the $20s in a year.
But the company isn't going to just stop growing! what? it's going to start paying dividends? you forget that there's going to be a whole market for CBD enriched strains which MDCN is developing with it's certified BCIT R&D team. Here's some of my DD on CBDs. Developing CBD enriched strains is part of the long-term plan for MDCN. This is not just about selling marijuana to people to smoke. it is about a much larger market that has yet to be realized:
The study:
www.ncbi.nlm.nih.gov/pubmed/12594529?dop...
www.ncbi.nlm.nih.gov/pubmed/15313899?dop...
"Because blockade of the VEGF pathway constitutes one of the most promising antitumoral approaches currently available, the present findings provide a novel pharmacological target for cannabinoid-based therapies"
CONCLUSIONS: Under the conditions of these 2-year gavage studies, there was no evidence of carcinogenic activity of 1-trans-delta(9)-tetrahydrocannabinol in male or female F344/N rats administered 12.5, 25, or 50 mg/kg. There was equivocal evidence of carcinogenic activity of THC in male and female B6C3F1 mice based on the increased incidences of thyroid gland follicular cell adenomas in 125 mg/kg groups. Increased incidences of thyroid gland follicular cell hyperplasia occurred in male and female mice, and increased incidences of hyperplasia and ulcers of the forestomach were observed in male mice. The incidences of mammary gland fibroadenomas and uterine stromal polyps were decreased in dosed groups of female rats, as were the incidences of pancreatic adenomas, pituitary gland adenomas, and interstitial cell adenomas of the testis in dosed male rats and liver neoplasms in dosed mice. These decreases were likely related to lower body weights in dosed animals. Synonyms: 3-Pentyl-6,6,9-trimethyl-6a,7,8,10a-tetrahydro-6h-dibenzo(b,d) pyran-1-ol; delta1-tetrahydrocannabinol; (-)-delta1-3,4-trans- tetrahydrocannabinol; delta(9)-tetrahydrocannabinon; THC; delta1-THC; delta(9)-THC
"These results reinforce the evidence of antitumoral properties of CBD, demonstrating its ability to limit tumor invasion, although the mechanism of its pharmacological effects remains to be clarified."
www.ncbi.nlm.nih.gov/pmc/articles/PMC1576089/
Just tell me when to stop....
"Cannabinoids bind to cannabinoid receptors CB(1) and CB(2) and have been reported to possess anti-tumorigenic activity in various cancers. However, the mechanisms through which cannabinoids modulate tumor growth are not well known.
This study provides novel insights into the crosstalk between CB(2) and CXCR4/CXCL12-signaling pathways in the modulation of breast tumor growth and metastasis. Furthermore, these studies indicate that CB(2) receptors could be used for developing innovative therapeutic strategies against breast cancer."
www.ncbi.nlm.nih.gov/pubmed/21915267?dop...
"Consistently, treatment with the cannabinoid receptor agonist R(-)-7-hydroxy-Delta(6)-tetra-hydrocannabinol-dimethylheptyl (HU210) or genetic ablation of the endocannabinoid-degrading enzyme fatty acid amide hydrolase (FAAH) resulted in protection against DNBS-induced colitis. Electrophysiological recordings from circular smooth muscle cells, performed 8 hours after DNBS treatment, revealed spontaneous oscillatory action potentials in CB1(-/-) but not in CB1(+/+) colons, indicating an early CB1-mediated control of inflammation-induced irritation of smooth muscle cells. DNBS treatment increased the percentage of myenteric neurons expressing CB1 receptors, suggesting an enhancement of cannabinoid signaling during colitis. Our results indicate that the endogenous cannabinoid system represents a promising therapeutic target for the treatment of intestinal disease conditions characterized by excessive inflammatory responses."
www.ncbi.nlm.nih.gov/pubmed/15085199?dop...
I'm so happy I got to buy some shares at 1.44, 1.49, 1.51, and 1.65......I won't start "trimming" until they hit $15
AI
